Telehealth Narcolepsy Prescribing: What Prescribers Can Do in Florida

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients through telehealth, you’re probably asking yourself: Can I even do this legally? What about prescribing stimulants remotely? And how does my state’s scope of practice affect what I can prescribe?

These are exactly the right questions. Narcolepsy management sits at the intersection of psychiatry, neurology, and sleep medicine—and when you add telehealth and controlled substances to the mix, the regulatory landscape gets complicated fast.

Here’s the reality: Yes, you can prescribe narcolepsy medications via telehealth—but the specifics depend heavily on whether you’re an MD/DO or a PMHNP, which state you’re licensed in, and what medications you’re prescribing. The good news? Most states now support telehealth prescribing for narcolepsy treatments, especially with the extended federal COVID-era flexibilities through at least the end of 2025.

Let me break down what you actually need to know to practice confidently and compliantly.

The Federal Landscape: DEA Telehealth Rules Extended Through 2025

First, the federal framework that makes most of this possible:

As of late 2024, the DEA and HHS extended the pandemic-era exemption that allows providers to prescribe Schedule II-V controlled substances via telehealth without an initial in-person examination through at least December 31, 2025. This means you can currently initiate stimulant therapy (Adderall, Ritalin) or other narcolepsy medications for a new patient you’ve never met in person, as long as you conduct a proper telehealth evaluation.

This is huge for narcolepsy care. Without this waiver, the Ryan Haight Act would require that first face-to-face visit before prescribing any controlled substance—a significant barrier for patients who may live hours from the nearest sleep specialist or psychiatrist, and who might not be able to drive safely due to their condition.

What happens after 2025? Nobody knows for certain. The DEA has proposed new telemedicine registration pathways that could make remote controlled-substance prescribing permanent, but details are still being hammered out. For now, you can operate under the extended rules, but stay alert to changes—platforms like ours will keep you updated on any new requirements.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What Psychiatrists Can Prescribe for Narcolepsy (and How)

If you’re a board-certified psychiatrist (MD or DO), you have full prescriptive authority for narcolepsy medications in every state. Your scope isn’t limited by the type of medication or schedule—you can prescribe:

• Schedule II stimulants (amphetamine salts, methylphenidate, dextroamphetamine)
• Schedule IV wakefulness promoters (modafinil, armodafinil)
• Schedule III medications (sodium oxybate/Xyrem for cataplexy)
• Newer agents (pitolisant/Wakix, solriamfetol/Sunosi)
• Adjunct medications (SSRIs or SNRIs for cataplexy, sedatives for nighttime sleep fragmentation)

The process via telehealth typically works like this:

1. Initial evaluation via video (audio-only generally won’t cut it for controlled substances). You’ll review the patient’s sleep study results (polysomnography and Multiple Sleep Latency Test), confirm the narcolepsy diagnosis, rule out mimickers like sleep apnea or depression causing hypersomnia, and take a thorough medication history.

2. PDMP check before prescribing any controlled substance. Nearly all states require this—you’ll check your state’s prescription drug monitoring program to see the patient’s controlled substance history. Some states like New York mandate a PDMP query before every controlled prescription.

3. E-prescribe the medication using a DEA-compliant electronic prescribing system. Paper prescriptions for Schedule II drugs are essentially obsolete, and most states now require or strongly prefer e-prescribing for controlled substances (EPCS).

4. Monthly follow-ups are standard practice for Schedule II medications (federal law prohibits refills, so you’re writing a new prescription each month anyway). These 15-20 minute visits focus on efficacy (is the patient staying awake?), side effects (blood pressure, heart rate, insomnia, appetite), and adherence.

5. Documentation as if it were in-person. Telehealth visits must meet the same standard of care—detailed notes, informed consent for telehealth, and justification for controlled substance prescribing.

State-Level Nuances for Psychiatrists

While your scope as a physician is consistent across states, some states impose telehealth-specific restrictions on controlled substance prescribing:

Florida is the main outlier. Florida law prohibits prescribing Schedule II controlled substances via telehealth unless it’s for a psychiatric disorder, inpatient/hospice care, or chronic pain management. Since narcolepsy is technically a neurological condition (not psychiatric), a strict reading means you can’t initiate Adderall for narcolepsy purely via telehealth in Florida. You could:

• Use Schedule IV alternatives (modafinil/armodafinil, which are allowed via telehealth under Florida’s 2022 law)
• Arrange an initial in-person exam with a Florida physician, then manage ongoing care via telehealth
• Make a case that you’re treating comorbid ADHD (a psychiatric disorder) if applicable

Most other states—California, Texas, New York, Pennsylvania, Illinois—don’t have Florida’s categorical ban. They allow controlled substance prescribing via telehealth as long as you meet standard of care requirements and the federal waiver is in effect.

PMHNP Prescribing Authority: It’s Complicated (and State-Dependent)

If you’re a Psychiatric-Mental Health Nurse Practitioner, your ability to prescribe narcolepsy medications independently varies dramatically by state. Here’s where scope of practice laws really matter.

Full-Practice and Near-Independent States

California: As of 2023, experienced NPs can practice under AB 890’s ‘103 NP’ category—working in a physician-supervised group setting but without individual physician oversight on each prescription. After accumulating at least 4,600 hours (about 3 years) and meeting requirements, you can apply for ‘104 NP’ status starting in 2026, which grants full independence. Until then, you need a standardized procedure agreement with a physician that covers controlled substances. California NPs can prescribe Schedule II-V drugs, including stimulants for narcolepsy, but the pathway requires physician collaboration initially.

New York: After completing 3,600 hours of practice (roughly 2 years) under a collaborative agreement, you no longer need any physician oversight. An experienced PMHNP in New York can prescribe narcolepsy medications—including Schedule II stimulants—completely independently via telehealth. Before hitting that 3,600-hour mark, you need a written collaborative agreement that covers controlled substances, but you can still prescribe them under that agreement.

Illinois: Full Practice Authority (FPA) is available after 4,000 hours of clinical experience plus 250 hours of pharmacology continuing education. Once you have FPA, you can prescribe Schedule II-V controlled substances independently. Illinois does require a consultation relationship with a physician if you’re prescribing Schedule II opioids long-term (with monthly documentation), but this doesn’t apply to stimulants or other narcolepsy meds. For stimulants, you’re good to go independently.

The bottom line in these states: Experienced PMHNPs can manage narcolepsy via telehealth nearly identically to psychiatrists. The main difference is the transitional period requiring collaboration before you reach independence.

Restricted-Practice States (Where PMHNPs Need Physician Support)

Texas: This is the most restrictive environment for PMHNPs treating narcolepsy. Texas requires a Prescriptive Authority Agreement with a supervising physician for any prescribing. Worse, Texas law prohibits NPs and PAs from prescribing Schedule II drugs in outpatient settings except in very narrow circumstances (hospital inpatient orders or hospice care).

What does this mean practically? A Texas PMHNP cannot prescribe Adderall or Ritalin for an outpatient narcolepsy patient. Your collaborating physician would need to write those prescriptions. You can prescribe modafinil (Schedule IV) under your prescriptive authority agreement, but for stimulant therapy, you’d need an MD/DO partner.

This makes Texas challenging for independent PMHNP telehealth practice focused on narcolepsy—you essentially need a physician co-managing the case.

Florida: PMHNPs must practice under a collaborative agreement with a psychiatrist (Florida’s autonomous NP pathway excludes psychiatric NPs). While you can prescribe Schedule II drugs, Florida limits NP prescriptions to a 7-day supply maximum—unless you’re a ‘certified psychiatric nurse’ prescribing psychiatric medications (which has an exemption).

The 7-day limit creates a significant workflow burden: instead of a monthly prescription, you’d be writing or calling in weekly scripts. Many Florida PMHNPs work around this by having their collaborating physician handle ongoing stimulant prescriptions, or by using modafinil (Schedule IV, no 7-day limit).

Also remember Florida’s telehealth restriction on Schedule II drugs applies to NPs just as it does to MDs (possibly even more strictly given the collaborative requirements).

Pennsylvania: You must have a written collaborative agreement with a physician to prescribe. State regulations limit you to a 30-day supply of Schedule II drugs (and 90-day supply for Schedule III-IV). This aligns reasonably well with monthly narcolepsy med checks, but you cannot extend prescriptions beyond 30 days without physician involvement. Your collaborating physician’s name must appear on prescriptions per pharmacy rules, and they must review a portion of your charts.

Pennsylvania is workable for PMHNP narcolepsy care—it just requires maintaining that collaborative relationship and sticking to monthly prescribing cycles.

The Practical Impact: Match Your Scope to Your State

What this means for you as a PMHNP:

• In New York, Illinois, or California (after meeting experience requirements), you can build a robust telehealth narcolepsy practice with minimal physician oversight—prescribing stimulants, managing titrations, handling follow-ups independently.

• In Texas, you’ll need a physician partner willing to prescribe Schedule IIs, limiting your autonomy. You can handle other aspects of care (therapy, sleep hygiene counseling, modafinil management) but not the primary stimulant therapy independently.

• In Florida and Pennsylvania, you can prescribe narcolepsy meds but with quantity/timeframe restrictions that create extra administrative work. Having a supportive collaborating physician is essential.

If you’re considering joining a telehealth platform to treat narcolepsy patients, make sure the platform understands these state-specific limitations and can support you with collaborative agreements where needed, or steers you toward states where you can practice at the top of your license.

Medication Management Workflow & Reimbursement Reality

Let’s talk about what treating narcolepsy via telehealth actually looks like day-to-day, and whether it’s financially viable.

The Clinical Workflow

Narcolepsy medication management is typically high-frequency, low-complexity compared to therapy-intensive psychiatric conditions:

• Initial evaluation (30-45 minutes): Review diagnosis, sleep study results, medication history, comorbidities, discuss treatment options, initiate medication, provide psychoeducation about narcolepsy and safety (e.g., don’t drive until symptoms controlled).

• Monthly follow-ups (15-20 minutes): Symptom check (Epworth Sleepiness Scale scores, any sleep attacks or cataplexy episodes?), side effect monitoring (blood pressure, weight, mood changes), dose adjustments, refill Schedule II prescription. These are efficient telehealth visits—perfect for video platforms.

• Quarterly or biannual check-ins for stable patients (if allowed by insurance and medication schedules): Longer review, coordinate with sleep specialists or primary care, handle prior authorizations for medications, discuss lifestyle modifications.

You’ll also spend non-visit time on:

• PDMP checks (required at each controlled prescription in most states)
• Prior authorizations for expensive medications like Xyrem, Wakix, or even modafinil (many insurers require PA despite generic availability)
• Coordination with sleep medicine or neurology if the patient needs repeat sleep studies or has complications

The Reimbursement Picture

Insurance billing: Most narcolepsy med checks are billed as E/M codes—typically 99213 or 99214 for established patient follow-ups. A 99213 (straightforward follow-up, low complexity) reimburses around $80-100 from Medicare and $100-140 from commercial payers. A 99214 (moderate complexity—dose adjustments, managing side effects) runs $110-130 Medicare, $140-160+ commercial.

Telehealth parity laws in most states (California, New York, Illinois, Pennsylvania, etc.) ensure you’re paid the same rate for video visits as in-person. This makes the economics work: you can see 4-5 brief follow-ups per hour via telehealth (allowing for documentation), generating solid hourly compensation.

The catch: Mental health providers historically get paid about 22% less than other specialists by private insurance, according to recent data—a mental health parity enforcement issue. Many psychiatrists have responded by going out-of-network and charging cash rates ($200-300 per session). For narcolepsy specifically, since it’s coded as a neurological condition (ICD-10 G47.4xx), some insurers may process it under medical rather than behavioral health benefits, potentially avoiding some of those reimbursement gaps.

Medicare considerations: If you’re an MD, Medicare reimburses at the full physician fee schedule. If you’re an NP billing under your own NPI, Medicare pays you 85% of the physician rate for the same service. (Many commercial payers pay NPs and MDs equally, but Medicare is explicit about the 85% rule.) This is worth considering for your income projections.

Platform models: Many telehealth platforms offer per-visit compensation ($60-100 per follow-up session) and handle all the billing, scheduling, and EHR for you. This removes the headache of dealing with insurers directly and provides predictable income. The trade-off is you earn less per session than if you were billing insurance yourself, but you eliminate all administrative overhead.

The Patient Acquisition Economics

Here’s something crucial providers often overlook: how much does it actually cost to get a narcolepsy patient into your practice?

If you’re building a practice from scratch through DIY marketing:

• SEO/content marketing takes 6-12 months of consistent investment ($2,000-5,000/month for agencies or your time) before generating meaningful traffic
• Google Ads for mental health keywords run $15-40+ per click, and conversion rates are brutal—you might spend $200-400+ to book one patient who actually shows up
• Directory listings (Psychology Today, Zocdoc) charge monthly fees ($30-100/month) plus booking fees ($35-100 per appointment on Zocdoc), and you’re competing with hundreds of other providers on the same page
• No-show rates from cold leads (people who found you via ads) are higher than warm referrals, wasting appointment slots

When you factor in all costs—ad spend, agency fees, staff time to qualify leads, failed campaign iterations—acquiring a qualified psychiatric patient through traditional marketing realistically costs $200-500+ each.

The telehealth platform value proposition: Instead of gambling thousands per month on marketing with uncertain ROI, you pay only when a qualified patient books with you. Platforms like Klarity use a pay-per-appointment model where you pay a standard listing fee per new patient lead—no upfront marketing spend, no monthly subscriptions eating into your income during slow months, and no wasted budget on clicks that don’t convert.

The patients are pre-qualified (already matched to your specialty and availability), the telehealth infrastructure is built-in (no separate platform costs), and you control your schedule—you only pay when you see patients. That’s guaranteed ROI versus the uncertainty of building your own patient pipeline from scratch.

For most providers, especially those starting out or scaling quickly, this removes the entire patient acquisition risk and lets you focus on what you do best: treating patients.

Navigating the Unique Challenges of Narcolepsy Care

Treating narcolepsy via telehealth has some distinctive pain points beyond general psychiatric practice:

Confirming the Diagnosis Remotely

Unlike depression or ADHD (which you can diagnose clinically), narcolepsy requires objective testing: polysomnography (overnight sleep study) plus a Multiple Sleep Latency Test (MSLT). As a telehealth provider, you’re usually seeing patients after a sleep specialist has made the diagnosis.

Best practice: Require documentation of diagnostic sleep studies before initiating treatment. If a patient claims narcolepsy but hasn’t had formal testing, you’ll need to refer them to a local sleep center—which can delay treatment by weeks or months. This is just the reality of responsible prescribing for this condition.

Some patients will come to you with vague diagnoses (‘my doctor thinks I might have narcolepsy’). Don’t start stimulants based on suspicion alone. Coordinate with their PCP or a sleep medicine physician to get proper testing arranged.

Managing Controlled Substance Risk

Narcolepsy’s first-line treatments are stimulants (Schedule II) or modafinil (Schedule IV)—medications with abuse potential that require careful monitoring:

• Tolerance and dose escalation: Patients may develop tolerance to stimulants over time and request higher doses. Some tolerance is expected, but rapid escalation or ‘lost prescriptions’ are red flags. Monthly PDMP checks help spot doctor shopping.

• Diversion risk: Stimulants are valuable on the black market. Document why higher doses are medically necessary, use pill counts occasionally (harder via telehealth, but you can ask patients to show bottles on video), and maintain thorough notes justifying dosing decisions.

• Safety monitoring: High-dose stimulants can raise blood pressure and heart rate. You’ll need patients to monitor these at home (with a home BP cuff) and report results. Arrange baseline EKGs through their PCP if prescribing high doses or if they have cardiac risk factors.

The Prior Authorization Gauntlet

Narcolepsy medications often require prior authorization, even for generic stimulants in some insurance plans:

• Modafinil/armodafinil: Despite being generic, many insurers require PA documentation that the patient has a confirmed narcolepsy diagnosis (not just being prescribed off-label for fatigue).

• Newer medications (Sunosi, Wakix): Almost always require PA, step therapy (proof you tried older stimulants first), and documentation of side effects or inadequate response to first-line treatments.

• Sodium oxybate (Xyrem/Xywav): This Schedule III medication for cataplexy has a Risk Evaluation and Mitigation Strategy (REMS) program. Prescribers must enroll, and the medication is dispensed only through a single central pharmacy. The paperwork and coordination are significant.

Plan for 30-60 minutes of unpaid administrative time per patient dealing with PA paperwork. Platforms that provide administrative support staff to handle these tasks are worth their weight in gold.

The Stimulant Shortage Nightmare

Since mid-2022, ongoing amphetamine shortages have severely disrupted narcolepsy care. Patients call panicked because their pharmacy can’t fill prescriptions. You’re stuck scrambling to:

• Find alternative pharmacies with stock
• Switch medications (e.g., from amphetamine to methylphenidate or modafinil)
• Re-titrate doses and manage the transition

As of early 2024, the shortage continued despite FDA/DEA pressure on manufacturers. Telehealth has a small advantage here: you can quickly e-prescribe alternatives and send to different pharmacies electronically. But it’s still an added stress that affects patient stability and increases your workload.

Sleep Medicine Coordination

Many narcolepsy patients benefit from ongoing relationships with sleep specialists, especially for:

• Repeat sleep studies if symptoms change
• Complex cases with unclear cataplexy or other parasomnias
• Cognitive behavioral therapy for insomnia (CBT-I) if they have comorbid sleep fragmentation

As a telehealth psychiatric prescriber, you’re often the accessible ongoing medication manager, while the sleep specialist is the diagnostic expert and consultant. Make sure you have pathways to coordinate care—shared records, periodic updates, referral networks.

State-by-State Summary: Where Can You Prescribe What?

Here’s a quick reference table for our key states:

The Takeaway for Providers

If you’re a psychiatrist: You can treat narcolepsy via telehealth in nearly any state right now, with Florida being the main exception requiring workarounds for Schedule II stimulants. Take advantage of the federal DEA waiver through 2025, but prepare for possible rule changes after that.

If you’re a PMHNP: Your ability to independently manage narcolepsy varies wildly by state:

• Best opportunities: New York, Illinois, California (after experience requirements)
• Workable with collaboration: Pennsylvania, Florida (with extra admin burden)
• Challenging: Texas (need MD partner for stimulants)

In restricted states, platforms that help you find and maintain collaborative agreements with physicians are essential. In full-practice states, you can build a thriving independent telehealth narcolepsy practice.

Why Narcolepsy Care Is a Growth Opportunity (Despite the Complexities)

You might be thinking: This sounds complicated. Why bother with narcolepsy when I could stick to anxiety and depression?

Fair question. Here’s why narcolepsy is worth adding to your telehealth practice:

Severe unmet need: Narcolepsy affects about 160,000 Americans (roughly 1 in 2,000 people), but most go undiagnosed or untreated for years. Sleep specialists are scarce—many patients wait 6+ months for appointments. Psychiatrists and PMHNPs who are comfortable managing this condition can fill a critical gap.

Long-term, stable patients: Once you get a narcolepsy patient’s medications dialed in, they typically need ongoing monthly or quarterly maintenance—providing steady, predictable income. These aren’t one-off crisis visits; they’re long-term relationships.

Medication-focused visits: Most follow-ups are brief (15-20 minutes), medication-focused appointments—high efficiency for telehealth. You can see 4-5 narcolepsy patients in the time one therapy session takes, making your hourly compensation competitive.

Less emotional labor than complex trauma or severe mental illness: While narcolepsy patients certainly struggle (stigma, functional impairment, frustration with their condition), the clinical work is primarily pharmacological problem-solving. If you find medication management intellectually satisfying but want a break from intensive psychotherapy, narcolepsy hits that sweet spot.

Low competition in telehealth: Many psychiatrists and PMHNPs shy away from narcolepsy because they’re unfamiliar with the condition or worried about controlled substance regulations. That means less competition for patients and potentially better reimbursement rates (patients struggling to find any provider are willing to pay out-of-pocket).

Advocacy and meaning: Narcolepsy patients often face discrimination and disbelief (‘you’re just lazy,’ ‘everyone gets tired’). Helping them access effective treatment and advocating for workplace or academic accommodations can be deeply rewarding. You’re literally helping people reclaim their lives.

How We Support Narcolepsy Prescribers on Our Platform

If you’re considering joining Klarity to treat narcolepsy patients via telehealth, here’s what we provide:

✅ Pre-qualified patient matching: We connect you with patients who already have a narcolepsy diagnosis and are looking for ongoing medication management—no wasting time on unqualified leads.

✅ Built-in compliance tools: Integrated PDMP checks, EPCS e-prescribing, telehealth consent workflows, and documentation templates that meet state and DEA requirements.

✅ Collaborative agreement support: In states requiring physician oversight for NPs (Texas, Pennsylvania, Florida), we can help facilitate those relationships or pair you with collaborating physicians already on the platform.

✅ Administrative support: Our team handles prior authorizations, insurance verification, and appointment scheduling so you can focus on clinical care, not paperwork.

✅ State-by-state guidance: We keep you updated on changing telehealth and controlled substance laws in each state where you’re licensed, so you don’t have to become a legal expert.

✅ Pay-per-appointment model: No upfront marketing spend, no monthly fees. You pay only when you see patients—guaranteed ROI with no financial risk.

✅ Both insurance and cash-pay patients: We work with major insurers (so you can bill traditional E/M codes) and also offer cash-pay options for patients who prefer out-of-network care or faster access.

Next Steps: Start Treating Narcolepsy Patients via Telehealth

Whether you’re a psychiatrist looking to expand your scope or a PMHNP who’s comfortable with controlled substance management, treating narcolepsy via telehealth is both clinically rewarding and financially viable—especially with the right platform support.

Check your state’s scope of practice using the table above. If you’re in a full-practice or reduced-practice state (NY, IL, CA), you’re set. If you’re in a restricted state (TX, FL, PA), make sure you have or can get a collaborative agreement in place.

Verify your DEA registration and PDMP access in each state where you’ll see patients. You’ll need both to prescribe controlled substances legally.

Join a telehealth platform that understands narcolepsy care—one that handles patient acquisition, provides compliance infrastructure, and supports you with admin tasks so you can focus on medicine.

Ready to explore how Klarity can help you treat narcolepsy patients compliantly and profitably? [Schedule a call with our provider team] to learn more about joining our network and accessing a steady stream of pre-qualified patients who need your expertise.

Frequently Asked Questions

Can I prescribe Adderall for narcolepsy via telehealth if I’ve never met the patient in person?

As of 2026, yes—under the extended DEA COVID-era waiver that runs through at least December 31, 2025. You must conduct a proper telehealth evaluation (video, not phone-only), verify the narcolepsy diagnosis (ideally with sleep study documentation), check the state PDMP, and follow all standard prescribing protocols. Check your specific state’s telehealth laws (Florida is the main exception with restrictions on Schedule II via telemedicine for non-psychiatric conditions).

What’s the difference between what a psychiatrist and PMHNP can prescribe for narcolepsy?

Psychiatrists (MD/DO) have full prescriptive authority in all states—no restrictions based on medication schedule or supervision requirements. PMHNPs’ authority varies by state: in full-practice states (New York after 3,600 hrs, Illinois with FPA, California as 104 NP), experienced NPs can prescribe narcolepsy meds nearly identically to MDs. In restricted states (Texas, Florida, Pennsylvania), NPs face limitations—Texas NPs can’t prescribe Schedule II stimulants in outpatient settings at all, Florida NPs have 7-day supply limits on Schedule IIs, and Pennsylvania NPs can only prescribe 30-day supplies.

Do I need a sleep medicine specialist to collaborate if I’m treating narcolepsy via telehealth?

Not legally required, but clinically wise. Most narcolepsy patients should have a sleep specialist who made the initial diagnosis via polysomnography and MSLT. As a psychiatrist or PMHNP, you’re typically managing ongoing medication after that diagnosis is confirmed. Coordinate with the sleep specialist for complex cases, repeat testing, or if symptoms don’t respond as expected to medication. You don’t need a formal collaborative agreement (unless your state requires one for other reasons), but having a referral pathway is good practice.

How often do narcolepsy patients need follow-up appointments?

Typically monthly during initial titration and dose optimization (which aligns with the monthly Schedule II prescription requirement anyway). Once stable, many providers stretch to every 3 months for routine med checks, though some insurers or pharmacy benefit managers require more frequent visits to authorize ongoing controlled substance prescriptions. Plan for at least quarterly visits for stable patients, with flexibility to increase frequency if symptoms change or side effects emerge.

What do I do if my narcolepsy patient’s pharmacy can’t fill their stimulant prescription due to shortages?

This has been a common issue since 2022. Your options: (1) E-prescribe to alternative pharmacies—call around to find who has stock; (2) Switch medications (e.g., from amphetamine to methylphenidate, or to modafinil if the patient’s insurance covers it and they haven’t tried it); (3) Work with the patient’s insurance to expedite prior authorization for alternative medications. Telehealth platforms with dedicated pharmacy liaison support can help navigate these situations faster than you can solo.

Are narcolepsy med management visits reimbursed the same as in-person visits?

In most states, yes—telehealth parity laws require insurance companies to reimburse telehealth visits at the same rate as in-person for the same service. States with strong parity laws include California, New York, Illinois, and Pennsylvania. Medicare also currently reimburses tele-mental health visits at in-person rates (with some potential changes pending after 2024). You’ll typically bill 99213 or 99214 E/M codes for narcolepsy follow-ups, just like you would for in-person med checks.

What happens after the DEA waiver expires in December 2025?

Uncertain—Congress may extend it again, or the DEA may finalize new telemedicine registration rules that allow continued remote prescribing under different requirements (possibly requiring a telemedicine-specific DEA registration). Worst case, you’d need to arrange an initial in-person visit before prescribing Schedule II drugs, though many states would likely create workarounds or the rules might grandfather existing patient relationships. Stay tuned to updates from your telehealth platform and professional organizations.

References

1. Axios, ‘COVID-era telehealth prescribing extended again through December 2025’ (Nov 18, 2024) – Reports DEA/HHS extension of Ryan Haight Act waiver for controlled substance prescribing via telehealth. www.axios.com

2. Texas Medical Board, ‘Who can prescribe Schedule II drugs under physician delegation?’ – Official FAQ clarifying Texas NP/PA cannot prescribe Schedule II in outpatient settings except hospital inpatient or hospice. www.tmb.state.tx.us

3. California Board of Registered Nursing, ‘AB 890 Implementation’ – Details California’s 103/104 NP pathway to independent practice, noting 104 NP certification begins in 2026 after 3-year transition. www.rn.ca.gov

4. Florida Statutes Section 464.012 (2021) – State law showing 7-day supply limit for NP Schedule II prescriptions with exception for psychiatric nurses prescribing psychiatric medications. www.flsenate.gov

5. Rivkin Radler, ‘New Law Allows Experienced NPs to Practice Independently in NY’ (Apr 13, 2022) –

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority